Evaluation of the Impact of Reduced Immunosuppression
Launched by METHODIST HEALTH SYSTEM · Feb 3, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
GVHD is commonly observed in allogeneic hematopoietic stem cell transplantation recipients but can also occur in recipients of solid organ transplantation , with the first case of GVHD in a SOT recipient described in 1984. While the exact incidence of SOT-associated GVHD has not been determined due to challenges with identifying and diagnosing GVHD in SOT recipients, the reported incidence of GVHD following orthotopic liver transplantation ranges from 0.1%-2%, one of the highest rates among SOT recipients. Although it occurs very rarely with SOT, GVHD leads to poor patient outcomes, with a ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥ 18 years
- • Received OLT or CKLT during study period
- Exclusion Criteria:
- • Recipients requiring re-transplant within one month post-transplant
- • Recipients who died of a cause other than GVHD within one month post-transplant
About Methodist Health System
Methodist Health System is a leading healthcare provider dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and scientific inquiry, the organization leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies across various therapeutic areas. Methodist Health System collaborates with healthcare professionals, researchers, and industry partners to enhance the understanding of diseases and develop new treatment modalities, ensuring that cutting-edge therapies are accessible to the communities it serves. Through its clinical trial initiatives, Methodist Health System aims to contribute to the evolving landscape of medicine while prioritizing patient safety and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Patients applied
Trial Officials
Jessica Crotty, PharmD
Principal Investigator
Methodist Health System
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials